Les formulations à forte teneur en alcool devront être soumises à une licence et à une ordonnance, le Centre modifiant les règles

The Indian government has taken a significant step toward tightening regulations on medicinal products containing high levels of alcohol. In a move aimed at curbing misuse and promoting safer consumption, the Union Ministry of Health and Family Welfare has amended the Drugs Rules, 1945, by removing the licensing exemption for formulations containing ethyl alcohol. These changes mark a shift in how such products are governed, bringing them under stricter oversight and requiring prescriptions for purchase. Previously, certain medicinal products—such as tinctures of cardamom, ginger, and other aromatic preparations—were exempted from licensing requirements under Schedule K of the Drugs Rules. This exemption allowed these products to be sold without formal licensing, even though some contained high concentrations of ethyl alcohol, ranging up to 80–90% v/v. Such high alcohol content made these formulations vulnerable to misuse, particularly for recreational purposes. Concerns were raised by state governments, who highlighted the potential risks associated with unregulated access to these products. The ministry's decision followed extensive consultations with the Drugs Technical Advisory Board, leading to the removal of the exemption and the placement of these products under Schedule H1. Under this new classification, all formulations containing more than 12% v/v ethyl alcohol and in quantities exceeding 30 mL must now undergo the licensing process outlined in the Drugs and Cosmetics Act, 1940. This means that manufacturers and distributors must secure appropriate licenses before marketing these products. The shift to Schedule H1 also introduces additional regulatory measures. Products classified under this schedule can only be sold upon presentation of a valid prescription from a registered medical practitioner. Furthermore, vendors are required to maintain detailed records of all sales for a period of at least three years. These steps aim to ensure that such products remain within the controlled pharmaceutical supply chain, reducing opportunities for diversion and unauthorized distribution. The change applies specifically to non-Ayurvedic, Unani, Siddha, or Homoeopathic formulations, as traditional systems of medicine are already subject to separate regulations. For example, Ayurvedic and Unani medicines have caps on alcohol content, typically set at 16%, while Homoeopathic medicines are limited to 12%. The new rule targets tinctures intended for digestive aid or similar uses, which had previously exploited the licensing exemption to produce and sell high-alcohol products in large volumes. Industry insiders revealed that some local manufacturers, particularly in rural and semi-urban areas, had taken advantage of the exemption to produce tinctures with high alcohol content, often laced with flavors like ginger or cardamom. These products were then sold in bulk, raising concerns about their potential for abuse. The government's intervention seeks to close this regulatory gap and prevent such practices from continuing unchecked. The amendment aligns with broader government initiatives to enhance drug regulation and promote responsible usage. By introducing stricter controls, the ministry aims to protect public health and ensure that medicinal products are available only for their intended therapeutic purposes. Officials emphasized that the changes would help curb the misuse of alcohol-containing formulations while maintaining their accessibility for legitimate medical applications. Looking ahead, the implementation of these amendments will likely involve a transition period during which existing stockpiles of exempt products may still be available. However, future production and distribution will be subject to the new licensing and prescription requirements. Industry stakeholders, healthcare professionals, and consumers will need to adapt to these changes, which represent a notable evolution in India's approach to regulating medicinal products.